The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Regulation of the immune response by the aryl hydrocarbon receptor
Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 558
Self-citationBalachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
Self-citationMetz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
Self-citationCharacterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Ball, H. J., Sanchez-Perez, A., Weiser, S., Austin, C. J. D., Astelbauer, F., Miu, J., McQuillan, J. A., Stocker, R., Jermiin, L. S., & Hunt, N. H. (2007) · Gene · doi:10.1016/j.gene.2007.04.010 · Cited by 434
Metz, R., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 384
Self-citationThéate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
Infectious tolerance via the consumption of essential amino acids and mTOR signaling
Cobbold, S. P., Adams, E., Farquhar, C. A., Nolan, K. F., Howie, D., Lui, K. O., Fairchild, P. J., Mellor, A. L., Ron, D., & Waldmann, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903919106 · Cited by 336
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A. S., Munn, D., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Self-citationTriplett, T. A., Garrison, K. C., Marshall, N., Donkor, M., Blazeck, J., Lamb, C., Qerqez, A., Dekker, J. D., Tanno, Y., Lu, W.-C., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4180 · Cited by 321
Self-citationBeatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 304
Yue, E. W., Sparks, R., Polam, P., Modi, D., Douty, B., Wayland, B., Glass, B., Takvorian, A., Glenn, J., Zhu, W., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00391 · Cited by 295
D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., & Hayaishi, O. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.129 · Cited by 292
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 270
Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
Safe, S., Lee, S.-O., & Jin, U.-H. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft128 · Cited by 264
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Self-citationMuller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
Self-citationHif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
Lee, K. E., Spata, M., Bayne, L. J., Buza, E. L., Durham, A. C., Allman, D., Vonderheide, R. H., & Simon, M. C. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0822 · Cited by 227
Ladomersky, E., Zhai, L., Lenzen, A., Lauing, K. L., Qian, J., Scholtens, D. M., Gritsina, G., Sun, X., Liu, Y., Yu, F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3573 · Cited by 203
Prendergast, G. C., Mondal, A., Dey, S., Laury-Kleintop, L. D., & Muller, A. J. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.11.005 · Cited by 196
Self-citationBanerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C., & Muller, A. J. (2008) · Oncogene · doi:10.1038/sj.onc.1210939 · Cited by 175
Self-citationTargeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173
Witkiewicz, A., Williams, T. K., Cozzitorto, J. A., Durkan, B., Showalter, S. L., Yeo, C. J., & Brody, J. R. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.014 · Cited by 158
Prendergast, G. C. (2011) · Nature · doi:10.1038/478192a · Cited by 155
Self-citationLi, M., Bolduc, A. R., Hoda, M. N., Gamble, D. N., Dolisca, S.-B., Bolduc, A., Hoang, K., Ashley, C., McCall, D. C., Rojiani, A. M., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-21 · Cited by 151
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Witkiewicz, A. K., Costantino, C. L., Metz, R. A., Muller, A. J., Prendergast, G. C., Yeo, C. J., & Brody, J. R. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.12.018 · Cited by 141
Self-citationIDO2 in Immunomodulation and Autoimmune Disease
Prendergast, G. C., Metz, R. A., Muller, A. J., Merlo, L. M. F., & Mandik‐Nayak, L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00585 · Cited by 140
Self-citationIndoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
Fox, E. E., Oliver, T., Rowe, M. M., Thomas, S., Zakharia, Y., Gilman, P. B., Muller, A. J., & Prendergast, G. C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00370 · Cited by 129
Self-citationMonjazeb, A. M., Kent, M. S., Grossenbacher, S. K., Minnar, C. M., Zamora, A. E., Mirsoian, A., Chen, M., Kol, A., Shiao, S. L., Reddy, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3026 · Cited by 111
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Mondal, A., Smith, C., DuHadaway, J. B., Sutanto‐Ward, E., Prendergast, G. C., Bravo‐Nuevo, A., & Muller, A. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.013 · Cited by 92
Self-citationSiu, L. L., Gelmon, K. A., Chu, Q. S.-C., Pachynski, R. K., Alese, O. B., Basciano, P. A., Walker, J., Mitra, P., Zhu, L., Phillips, P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct116 · Cited by 88
Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P. J., Metz, R. A., & Prendergast, G. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3613 · Cited by 65
Self-citationIDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients
Wang, W., Huang, L., Jin, J., Jolly, S., Zang, Y., Wu, H., Yan, L., Pi, W., Li, L., Mellor, A. L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2995 · Cited by 65
Gibney, G. T., Hamid, O., Gangadhar, T. C., Lutzky, J., Olszanski, A. J., Gajewski, T. F., Chmielowski, B., Boasberg, P. D., Zhao, Y., Newton, R. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3010 · Cited by 52
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
DAUD, A. I., Saleh, M. N., Hu, J. S., Bleeker, J. S., Riese, M. J., Meier, R., Zhou, L., Serbest, G., & Lewis, K. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9511 · Cited by 52
Nevler, A., Muller, A. J., Sutanto‐Ward, E., DuHadaway, J. B., Nagatomo, K., Londin, E. R., O’Hayer, K., Cozzitorto, J. A., Lavu, H., Yeo, T. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0814 · Cited by 48
Self-citationJoshi, M., Kulkarni, A. P., & Pal, J. K. (2013) · Biochimie · doi:10.1016/j.biochi.2013.07.030 · Cited by 38
Zakharia, Y., McWilliams, R. R., Shaheen, M., Grossman, K. F., Drabick, J. J., Milhem, M. M., Rixie, O., Khleif, S. N., Lott, R. E., Kennedy, E. P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct117 · Cited by 37
Self-citationJohnson, T. S., McGaha, T. L., & Munn, D. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_7 · Cited by 35
Eleftheriadis, T., Pissas, G., Yiannaki, E. E., Markala, D., Arampatzis, S., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.08.268 · Cited by 29
Muller, A., Mandik-Nayak, L., & Prendergast, G. (2010) · Immunotherapy · doi:10.2217/imt.10.22 · Cited by 26
Self-citationMetabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.
Giannakis, M., Li, H., Jin, C., Gopal, S., Desai, K. D., Horak, C. E., Wind‐Rotolo, M., Allen, E. M. V., Clish, C. B., Hodi, F. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3036 · Cited by 26
Zhang, Q., Zhang, Y., Boer, J., Shi, J. G., Hu, P., Diamond, S., & Yeleswaram, S. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074609 · Cited by 14
Nevler, A., Muller, A. J., Cozzitorto, J. A., Goetz, A. B., Winter, J. M., Yeo, T. P., Lavu, H., Yeo, C. J., Prendergast, G. C., & Brody, J. R. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2017.12.052 · Cited by 5
Self-citation
Cited by
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571892 · Cited by 640
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.038 · Cited by 559
Human Disease Ontology 2018 update: classification, content and workflow expansion
Schriml, L. M., Mitraka, E., Munro, J., Tauber, B., Schor, M., Nickle, L., Felix, V., Jeng, L., Bearer, C., Lichenstein, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1032 · Cited by 483
Metadata
- Authors
- Muller, A. J., Manfredi, M. G., Zakharia, Y., & Prendergast, G. C.
- Venue
- Seminars in Immunopathology
- Published
- 2018-09-10
- Volume
- 41
- Issue
- 1
- Pages
- 41-48
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2890642520
- Cited by
- 262
- References
- 56
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.